PLANO, Texas, July 22, 2025 /PRNewswire/ — FinThrive, Inc., a leading healthcare revenue cycle management software-as-a-service (SaaS) provider, today released a new infographic outlining the timeline and impact of key healthcare policy provisions included in the One Big Beautiful Bill Act (OBBBA). The visual resource highlights policy changes and implementation dates that affect patients, providers, payers, and healthcare systems—offering clear, concise insight into how the law’s most significant reforms will unfold over the next several years.
The infographic breaks down major initiatives such as Medicaid work requirements, Medicare eligibility tightening, and changes to state-directed Medicaid payments. Each policy entry includes key dates, expected impacts, and stakeholder implications to help healthcare leaders plan ahead and stay compliant.
This resource is part of FinThrive’s ongoing effort to help health systems, payers, and providers confidently navigate regulatory change.
About FinThrive
FinThrive helps healthcare organizations increase revenue, reduce costs, expand cash collections, and ensure regulatory compliance across the entire revenue cycle continuum. Providing one of healthcare’s most comprehensive and intelligent revenue cycle management SaaS platforms, FinThrive’s holistic and AI-driven approach to revenue optimization offers patient access, charge integrity, claims management, contract management, automation, data and analytics, and education solutions. Three out of five U.S. hospitals and health systems are using FinThrive today. For more information, visit finthrive.com.
SOURCE FinThrive, Inc.
NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…
"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…
WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…